US Stock MarketDetailed Quotes

PBLA Panbela Therapeutics

  • 0.590
  • +0.010+1.72%
Close Apr 12 16:00 ET
2.86MMarket Cap-1P/E (TTM)

About Panbela Therapeutics Company

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.

Company Profile

Company NamePanbela Therapeutics
CEODr. Jennifer K Simpson, PhD
MarketPink Market
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address712 Vista Boulevard,Suite 305
CountryUnited States of America
Zip Code55387

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Jennifer K Simpson, PhD
  • Director, President and Chief Executive Officer
  • 694.32K
  • Susan Horvath
  • Vice President, Finance, Principal Accounting Officer, Chief Financial Officer, Secretary and Treasurer
  • 423.46K
  • Jeffrey S. Mathiesen
  • Vice Chairman of the Board and Lead Independent Director
  • 81.50K
  • Dr. Michael T. Cullen, M.B.A.,M.D.
  • Chairman of the Board
  • 72.50K
  • Jeffrey E. Jacob
  • Director
  • 20.00K
  • Arthur J. Fratamico, R.Ph.
  • Independent Director
  • 49.00K
  • D. Robert Schemel
  • Independent Director
  • 57.50K
  • Daniel J. Donovan
  • Independent Director
  • 26.25K


Analyst Rating

No Data

Price Target

No Data

Heat List
Latest Price